6996 related articles for article (PubMed ID: 10496599)
1. Ber-H2 (CD30) immunohistochemical staining in malignant melanoma.
Polski JM; Janney CG
Mod Pathol; 1999 Sep; 12(9):903-6. PubMed ID: 10496599
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.
Kneile JR; Tan G; Suster S; Wakely PE
Histopathology; 2006 Jun; 48(7):855-61. PubMed ID: 16722935
[TBL] [Abstract][Full Text] [Related]
3. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous CD30-positive anaplastic large cell lymphoma analysis.
Shi Q; Zhou X; Yan X; Xu X; Yin H; Zhong T; Shamoto M; Qian B
Chin Med J (Engl); 2002 Dec; 115(12):1802-5. PubMed ID: 12622927
[TBL] [Abstract][Full Text] [Related]
5. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy.
Sung MT; Jones TD; Beck SD; Foster RS; Cheng L
Hum Pathol; 2006 Jun; 37(6):662-7. PubMed ID: 16733205
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of CON6D/B5: a new CD30 monoclonal antibody.
Lau SK; Thomas P; Weiss LM
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):273-7. PubMed ID: 20090517
[TBL] [Abstract][Full Text] [Related]
7. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.
Latza U; Foss HD; Dürkop H; Eitelbach F; Dieckmann KP; Loy V; Unger M; Pizzolo G; Stein H
Am J Pathol; 1995 Feb; 146(2):463-71. PubMed ID: 7856755
[TBL] [Abstract][Full Text] [Related]
8. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
Eyden B; Pandit D; Banerjee SS
Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
[TBL] [Abstract][Full Text] [Related]
9. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
11. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Schaefer C; Noppen C; Böni R; Kamarashev J; Nestle FO; Spagnoli GC; Dummer R
Am J Pathol; 1997 Dec; 151(6):1549-53. PubMed ID: 9403705
[TBL] [Abstract][Full Text] [Related]
12. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells.
Mahmood MN; Lee MW; Linden MD; Nathanson SD; Hornyak TJ; Zarbo RJ
Mod Pathol; 2002 Dec; 15(12):1288-93. PubMed ID: 12481009
[TBL] [Abstract][Full Text] [Related]
14. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
15. Utility of CD15, CD30 & CD45 in the immunohistochemical diagnosis of Hodgkin's disease by antigen retrieval method.
Arici DS; Aker H; Güngör M
Indian J Med Res; 1999 Jan; 109():33-7. PubMed ID: 10489740
[TBL] [Abstract][Full Text] [Related]
16. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
Isabel Zhu Y; Fitzpatrick JE
J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
[TBL] [Abstract][Full Text] [Related]
17. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
18. CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland.
Forconi F; Bocchia M; Marconcini S; Bigazzi C; Milani M; Fraternali-Orcioni G; Lauria F
Haematologica; 1999 Oct; 84(10):946-8. PubMed ID: 10509044
[TBL] [Abstract][Full Text] [Related]
19. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
20. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
